Literature DB >> 3114437

Irreversible encephalopathy with ifosfamide/mesna.

E Salloum, F Flamant, M Ghosn, N Taleb, C Akatchereian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3114437     DOI： 10.1200/JCO.1987.5.8.1303

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

3.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 5.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

Review 6.  Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.

Authors:  Karen I Sweiss; Rakesh Beri; Stacy S Shord
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

8.  Inflammatory Surrogate Parameters for Predicting Ifosfamide-Induced Neurotoxicity in Sarcoma Patients.

Authors:  Moritz Schmidt; Katrin Benzler; Ulrich M Lauer; Lars Zender; Clemens Hinterleitner; Martina Hinterleitner
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

9.  Ifosfamide-Induced Metabolic Encephalopathy in 2 Patients With Cutaneous T-Cell Lymphoma Successfully Treated With Methylene Blue.

Authors:  Anusha Vakiti; Ravi Pilla; Muhamad Alhaj Moustafa; Jacinth J Joseph; Aarthi G Shenoy
Journal:  J Investig Med High Impact Case Rep       Date:  2018-07-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.